ClinicalTrials.gg
Not yet recruitingNCT07751835Updated Aug 7, 2026

Effect of Height Based vs Conventional Dose of Spinal Anesthesia in Lower Limb Surgeries

A Phase 1/2 interventional study of Height based dose of hyperbaric bupivacaine 0.5% in Lower Limb Surgeries, sponsored by Liaquat National Hospital & Medical College. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Liaquat National Hospital & Medical College · Phase 1/2, Interventional, and Supportive care

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aim is to compare height based dose of spinal anesthesia vs conventional dose. Hypothesis is height based dose has less hemodynamics changes compared to conventional dosing.

Read the detailed description

This is a prospective, randomized, double blinded, controlled trial with minimum 6 months of data collection. Patients will be divided into two groups randomly. Group H and C each having 52 patients. Groups H will be given spinal anesthesia dose according to their height by pre determined dosing algorithm. Group C will be given a fixed dose of Hyperbaric Bupivacaine 0.5% 12.5mg (2.5ml) without adjusting it according to their height. Pateint's blood pressure and Heart rate along with sensory effect will be recorded 5,10 and 15 minutes later after spinal anesthesia. I will be recording any episode of bradycardia and hypotension and intervention needed to treat it in both the groups

02

Conditions studied

  • Lower Limb Surgeries
03

In context

Lead sponsor

Liaquat National Hospital & Medical College is the lead sponsor of 33 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • both genders. 18-65 years age I and II

Exclusion criteria

Exclusion Criteria:

  • and IV Refusal of patient Height less than 150 cm Known allergy to study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Active comparator
    height based spinal anesthesia dose

    Height based dose

    Drug: Height based dose of hyperbaric bupivacaine 0.5%

  • Active comparator
    Conventional dose of spinal anesthesia

    Conventional dose of hyperbaric bupivacaine 0.5%

    Drug: Height based dose of hyperbaric bupivacaine 0.5%

Interventions

  • DrugHeight based dose of hyperbaric bupivacaine 0.5%

    Height based vs Conventional dosing of spinal anesthesia in lower limb surgeries

06

What researchers measure

Primary outcomes

  1. Hypotension and Bradycardia

    Time frame: 6 months

  2. Icidence of hypotension and bradycardia

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 7, 2026
StartEst.
Aug 20, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Aug 1, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07751835
Lead sponsor
Liaquat National Hospital & Medical College
Responsible party
Zuniara Siddqui (Principal investigator, Liaquat National Hospital & Medical College) — Principal investigator
First posted
Aug 7, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
Dec 20, 2026 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion